

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
AGY Therapeutics, Inc.	09/20/2005

RECEIVING PARTY DATA

Name:	General Electric Capital Corporation
Street Address:	83 Wooster Heights Road
City:	Danbury
State/Country:	CONNECTICUT
Postal Code:	06810

PROPERTY NUMBERS Total: 53

Property Type	Number
Application Number:	10491509
Application Number:	11016387
Patent Number:	6841351
Application Number:	10116437
Patent Number:	6876930
Patent Number:	6470277
Application Number:	10229912
Patent Number:	6586239
Patent Number:	6660483
Patent Number:	6521414
Application Number:	10246837
Application Number:	10633109
Application Number:	10001051
Patent Number:	6455026
Application Number:	09983000

PATENT

500071095

REEL: 017015 FRAME: 0108

CH \$2120.00 10491509

Application Number:	10652981
Application Number:	10328544
Application Number:	10340123
Application Number:	10386971
Application Number:	10407365
Patent Number:	6846641
Application Number:	10745760
Application Number:	10764292
Application Number:	10795148
Application Number:	10868423
Application Number:	10868267
Application Number:	10910159
Application Number:	10868048
Application Number:	10669382
Application Number:	10943686
Application Number:	10973858
Application Number:	10974148
Application Number:	10027807
Application Number:	11097728
Application Number:	11107597
Application Number:	11008354
Application Number:	60676344
Application Number:	60707115
Application Number:	60709606
Application Number:	60711562
Application Number:	60713634
Application Number:	10293071
Application Number:	10293017
Application Number:	10307700
Application Number:	10307776
Application Number:	10406990
Application Number:	10408029
Application Number:	10430730
Application Number:	10430825
Application Number:	10681059

Application Number:	10449949
Application Number:	10971615
Application Number:	10112667

CORRESPONDENCE DATA

Fax Number: (214)981-3400
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 214-981-3483
Email: dclark@sidley.com
Correspondent Name: Dusan Clark, Esq.
Address Line 1: Sidley Austin LLP
Address Line 2: 717 N. Harwood St. Suite 3400
Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER:	22273-30020
NAME OF SUBMITTER:	Dusan Clark

Total Attachments: 8
source=001#page1.tif
source=001#page2.tif
source=001#page3.tif
source=001#page4.tif
source=001#page5.tif
source=001#page6.tif
source=001#page7.tif
source=001#page8.tif

**CONFIRMATORY GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS**

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (the "Grant") is made effective as of September 20, 2005 by and from AGY Therapeutics, Inc. (the "Grantor"), a Delaware corporation, whose principal address is 270 E. Grand Avenue, South San Francisco, CA 94080 to and in favor of General Electric Capital Corporation (the "Grantee"), a Delaware corporation, whose principal address is 83 Wooster Heights Road, Danbury, CT 06810, for itself and as Agent for the Lenders (as defined in the Security Agreement referenced below).

WHEREAS, Grantor and Grantee have entered into a Master Security Agreement dated August 15, 2000 (as amended from time to time, the "Security Agreement").

WHEREAS, the Grantor owns the patents and/or patent applications (the "Patents") listed on Exhibit A attached hereto, which Patents are pending, published and/or registered with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been granted in conjunction with the security interest granted to Grantee under the Security Agreement. The rights and remedies of Grantee with respect to the security interest granted herein are without prejudice to and are in addition to those set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the Security Agreement.

2) The Security Interest.

(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of all the Indebtedness of Grantor, pursuant to the Security Agreement. Upon the payment in full of the Indebtedness (other than contingent indemnification obligations), Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to Grantor all reasonably requested instruments in writing releasing the security interest in the Patents acquired under this Confirmatory Assignment.

(b) The Grantor hereby grants to Grantee a security interest in (1) all of Grantor's right, title and interest in and to the Patents set forth in Exhibit A now owned or from time to time after the date hereof owned or acquired by the Grantor, together with (2) all proceeds and products of the Patents, (3) the goodwill associated with such Patents, and (4) all causes of action arising prior to or after the date hereof for infringement of the Patents or unfair competition regarding the same.

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant of Security Interest effective as of the date first written above.

AGY Therapeutics, Inc.

By: Timothy McBride

Name: TIMOTHY McBRIDE

Title: PRESIDENT & CEO

STATE OF _____)
_____ COUNTY)

_____, known to me to be the _____ of _____, personally came before me this _____ day of _____, 2005, and executed or acknowledged to me that he executed the foregoing Grant of Security Interest in United States Patents on behalf of _____ and pursuant authority duly received.

(SEAL) _____
Notary Public, State of _____
My Commission Expires: _____

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of

San Mateo

SS.

On January 12, 2006 before me,

Rebecca Taylor

Name and Title of Officer (e.g., "Jane Doe, Notary Public")


personally appeared

Timothy McBride

Name(s) of Signer(s)

☒ personally known to me

☐ proved to me on the basis of satisfactory evidence



to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

R. D. Taylor
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document:

Confirmatory Grant of security interest in USA Patent.

Document Date:

September 20, 2005

Number of Pages:

Signer(s) Other Than Named Above:

Capacity(ies) Claimed by Signer

Signer's Name:

Timothy McBride

☒ Individual

☒ Corporate Officer -- Title(s):

President & CEO

☐ Partner -- ☐ Limited ☐ General

☐ Attorney-in-Fact

☐ Trustee

☐ Guardian or Conservator

☐ Other:

Signer Is Representing:

AGX Therapeutics Inc.

RIGHT THUMBPRINT OF SIGNER

Top of thumb here

PATENT PORTFOLIO FOR AGY THERAPEUTICS, INC.*
REVISED SEPTEMBER 2005

PATENT NO./ PUBLICATION NO.	TITLE	APP. NO.
20050053936	HIGH-THROUGHPUT TRANSCRIPTOME AND FUNCTIONAL VALIDATION ANALYSIS	10/491509
20050137209	TREATMENT OF NEUROLOGIC DISORDERS WITH INHIBITORS OF 11BETA-HSD1	11/016387
6841351	HIGH-THROUGHPUT TRANSCRIPTOME AND FUNCTIONAL VALIDATION ANALYSIS	10/027807
20030082570	HIGH-THROUGHPUT TRANSCRIPTOME AND FUNCTIONAL VALIDATION ANALYSIS	10/116437
6876930	AUTOMATED PATHWAY RECOGNITION SYSTEM	10/090698
6470277	TECHNIQUES FOR FACILITATING IDENTIFICATION OF CANDIDATE GENES	09/628202
20030054394	TECHNIQUES FOR FACILITATING IDENTIFICATION OF CANDIDATE GENES	10/229912
6586239	PURIFYING MICROGLIAL CELLS BY BINDING CELL FC RECEPTOR TO IMMUNOGLOBULIN G FC DOMAIN	09/479589
6660483	DIAGNOSTIC MARKER FOR NEUROLOGICAL CONDITIONS	09/688078
6521414	METHODS FOR IDENTIFYING A MODULATOR OF THE INTERACTION OF NMDA RECEPTOR WITH PROTEIN TYROSINE PHOSPHATASE L1	09/774481
20030092071	INTERACTION OF NMDA RECEPTOR WITH PROTEIN TYROSINE PHOSPHATASE	10/246837
20040072275	INTERACTION OF NMDA RECEPTOR WITH PROTEIN TYROSINE PHOSPHATASE	10/633109
6670138	METHODS OF DIAGNOSING, PREVENTING AND TREATING	10/001051

**PATENT PORTFOLIO FOR AGY THERAPEUTICS, INC.*
REVISED SEPTEMBER 2005**

PATENT NO./ PUBLICATION NO.	TITLE	APP. NO.
	NEUROLOGICAL DISORDERS AND NEURONAL INJURIES	
6455026	USE OF PROTEIN TYROSINE PHOSPHATASE ZETA AS A BIOMOLECULAR TARGET IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	09/816703
20030118585	USE OF PROTEIN BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	09/983000
20050074400	USE OF PROTEIN BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	10/652981
20030175209	USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF TUMORS	10/328544
20030190653	REGULATED GENE IN THE PATHOPHYSIOLOGY OF ISCHEMIC STROKE	10/340123
20050074831	INTERACTION OF NMDA RECEPTOR WITH PROTEIN SERINE THREONINE PHOSPHATASES	10/386971
20040001841	USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	10/407365
6846641	IN VITRO ISCHEMIA MODEL	10/131731
20040191312	5-HT3 RECEPTOR AGONISTS AS NEUROPROTECTORS	10/745760
20040226055	ANIMAL MODEL EXHIBITING PATHOLOGICAL CONDITIONS OF ALZHEIMER'S DISEASE	10/764292
20040224337	USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF TUMORS	10/795148
20050059689	SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECOVERY	10/868423

**PATENT PORTFOLIO FOR AGY THERAPEUTICS, INC.*
REVISED SEPTEMBER 2005**

PATENT NO./ PUBLICATION NO.	TITLE	APP. NO.
20050032827	SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECOVERY	10/868267
20050118644	INTERACTION OF NMDA RECEPTOR WITH PROTEIN TYROSINE PHOSPHATASE	10/910159
20050020483	SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECOVERY	10/868048
20050064385	HIGH-THROUGHPUT TURBIDOMETRIC ASSAY FOR SCREENING INHIBITORS OF PROTEIN DISULFIDE ISOMERASE ACTIVITY	10/669382
20050106745	COMBINATION OF SOLUBILITY AND MEMBRANE PERMEABILITY MEASUREMENT METHODS FOR PROFILING OF CHEMICAL COMPOUNDS	10/943686
US-2005-017603	REGULATED NUCLEIC ACIDS IN PATHOGENESIS OF ALZHEIMER'S DISEASE	10/973,858
20050123962	REGULATED NUCLEIC ACIDS IN PATHOGENESIS OF ALZHEIMER'S DISEASE	10/974148
	HIGH-THROUGHPUT TRANSCRIPTOME ANALYSIS	10027807
	MONOCLONAL ANTIBODIES DIRECTED TO RECEPTOR PROTEIN TYROSINE PHOSPHATASE ZETA	11/097,728
	MODULATION OF HEMIN KINASE FOR THE DIAGNOSIS AND TREATMENT OF ISCHEMIC STROKE	10/971,615
	INTERACTION OF THE NMDA RECEPTOR WITH THE PROTEIN TYROSINE PHOSPHATASE STEP IN PSYCHOTIC DISORDERS	11/107,597
	INTERACTION OF NMDA RECEPTOR WITH THE PROTEIN	11/008,354

PATENT PORTFOLIO FOR AGY THERAPEUTICS, INC.*
REVISED SEPTEMBER 2005

PATENT NO./ PUBLICATION NO.	TITLE	APP. NO.
	TYROSINE PHOSPHATASE STEP IN PSYCHOTIC DISORDERS	60/676,344
	DISCORDIN DOMAIN RECEPTOR- 1A(DDRIA) PROMOTES GLIOMA CELL INVASION AND ADHESION IN ASSOCIATION WITH MATRIX METALLOPROTEINASE-2	
	PIPERAZINE DERIVATIVES {ID #131}	60/707,115
	THERAPEUTIC PYRAZOLES {ID#37}	60/709,606
	THERAPEUTIC COMPOUNDS {ID#136}	60/711,562
	THERAPEUTIC UREA DERIVATIVES {ID#139}	60/713,634
	METHODS OF DIAGNOSING, PREVENTING AND TRACKING NEUROLOGICAL DISORDERS AND NEURONAL INJURIES	10/112,667
	REGULATED GENES IN THE PATHOPHYSIOLOGY OF ISCHEMIC STROKE	10/293,071
	REGULATED GENES IN THE PATHOPHYSIOLOGY OF ISCHEMIC STROKE	10/293,017
	ISCHEMIC ASSOCIATED GENES	10/307,700
	ISCHEMIC ASSOCIATED GENES	10/307,776
	USE OF MHC CLASS II TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	10/406,990
	USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	10/408,029
	NUCLEIC ACIDS ASSOCIATED WITH NEURODEGENERATIVE DISORDERS	10/430,730
	USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS	10/430,825

**PATENT PORTFOLIO FOR AGY THERAPEUTICS, INC.*
REVISED SEPTEMBER 2005**

PATENT NO./ PUBLICATION NO.	TITLE	APP. NO.
	PROTEIN INTERACTORS WITH NMDA RECEPTOR	10/681,059
	REGULATED NUCLEIC ACIDS IN PATHOGENESIS OF ALZHEIMER'S DISEASE	10/449,949
	THE ROLE OF HEMIN KINASE IN THE PATHOPHYSIOLOGY OF ISCHEMIC STROKE	10/971,615